Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010 Dec 1;52(6):1906-14. doi: 10.1002/hep.23947
Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010 Oct 1;52(4):1193-200.
Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.
Davis KL, Mitra D, Leteneux C, Bapat B, Naujoks C. Medical service utilization and costs by disease severity, sustained viral response, and genotype in European patients with chronic hepatitis c virus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A71.
Davis KL, Mitra D, Leteneux C, Bapat B, Naujoks C. Utilization and cost of peginterferon plus ribavirin combination therapy in the management of chronic hepatitis c virus in Europe. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A73-4.